Organic nitrates have been used clinically in the treatment of ischemic heart disease for more than a century. Recently, xanthine oxidase (XO) has been reported to catalyze organic nitrate reduction under anaerobic conditions, but questions remain regarding the initial precursor of nitric oxide (NO) and the link of organic nitrate to the activation of soluble guanylyl cyclase (sGC). To characterize the mechanism of XO-mediated biotransformation of organic nitrate, studies using electron paramagnetic resonance spectroscopy, chemiluminescence NO analyzer, NO electrode, and immunoassay were performed. The XO reducing substrates xanthine, NADH, and 2,3-dihydroxybenz-aldehyde triggered the reduction of organic nitrate to nitrite anion (NO 2 ؊ ). Studies of the pH dependence of nitrite formation indicated that XO-mediated organic nitrate reduction occurred via an acid-catalyzed mechanism. In the absence of thiols or ascorbate, no NO generation was detected from XO-mediated organic nitrate reduction; however, addition of L-cysteine or ascorbate triggered prominent NO generation. Studies suggested that organic nitrite (R-O-NO) is produced from XO-mediated organic nitrate reduction. Further reaction of organic nitrite with thiols or ascorbate leads to the generation of NO or nitrosothiols and thus stimulates the activation of sGC. Only flavin site XO inhibitors such as diphenyleneiodonium inhibited XO-mediated organic nitrate reduction and sGC activation, indicating that organic nitrate reduction occurs at the flavin site. Thus, organic nitrite is the initial product in the process of XO-mediated organic nitrate biotransformation and is the precursor of NO and nitrosothiols, serving as the link between organic nitrate and sGC activation.
Organic nitrates such as glyceryl trinitrate (GTN)1 and isosorbide dinitrate (ISDN) have been used clinically in the treatment of cardiovascular disease for more than a century.The beneficial effects of organic nitrates result primarily from their vasodilator properties, which have been attributed to their metabolic product, nitric oxide (NO) (1-4). In 1998, the Nobel Prize was awarded for the discovery of "nitric oxide as a signaling molecule in the cardiovascular system." It is well known that organic nitrates require enzymatic metabolism to generate bioactive NO; however, the molecular mechanisms of their biotransformation have not been fully elucidated.It has been reported that flavoenzymes play important roles in the bioactivation of organic nitrates (5-9), and the flavin inhibitor diphenyleneiodonium chloride (DPI) has shown strong inhibition of the bioactivation of organic nitrate (6, 10). Xanthine oxidase (XO) is a ubiquitous flavoenzyme in mammalian cells. XO plays a variety of important roles in normal physiology and disease, and it is the only identified enzyme that can mediate organic nitrate and inorganic nitrate/nitrite reduction (11)(12)(13)(14). It has been reported that XO can catalyze organic nitrate reduction to nitrite anion (NO 2 Ϫ ) under anaerobic conditions (13), ...